May 16, 2026 Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
May 16, 2026 InTest Reports Strong First Quarter 2026 Revenue of $33.9 Million, EPS of $0.06 and Adjusted EPS (Non-GAAP) of $0.16
May 16, 2026 Tech-Enabled, Lightweight Aesthetics and Green Sustainability: A Close Look at Health & Recreation Category of 139th Canton Fair
